https://www.optimumcomms.com/wp-content/uploads/2023/02/Heidelberg_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-23 12:51:002024-09-23 12:51:00Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/Heidelberg_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-23 12:51:002024-09-23 12:51:00Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-23 08:32:402024-09-23 08:32:40Biocomposites to showcase innovations in infection management at EBJIS 2024
https://www.optimumcomms.com/wp-content/uploads/2024/09/Vicebio_Logo_300x180px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-23 08:24:562024-09-24 11:22:17Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine
https://www.optimumcomms.com/wp-content/uploads/2024/09/Renovos-logo.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-19 08:36:102024-09-19 10:40:46Renovos Biologics strengthens its Board’s US expertise with appointment of Lisa Ferrara
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-18 08:40:392024-09-18 08:40:39Poolbeg Pharma plc – Interim results for the six months to 30 June 2024
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-18 08:32:462024-09-18 08:32:46Biocomposites acquires remaining shares in manufacturers of SYNICEM™ and Subiton products
https://www.optimumcomms.com/wp-content/uploads/2024/09/Minervax_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-17 08:46:382024-09-19 10:41:25MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus
https://www.optimumcomms.com/wp-content/uploads/2023/02/Alchemab_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-12 13:14:262024-09-12 13:14:26Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
https://www.optimumcomms.com/wp-content/uploads/2024/09/QL-Biopharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-12 10:56:122024-09-12 10:57:33QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel Once-Monthly GLP-1RA ZT002 at EASD 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-12 08:36:132024-09-12 08:36:13Biocomposites to distribute its NanoBone® product range in the UK
https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-10 08:45:382024-09-10 08:45:38Sofinnova Partners appoints Karl Naegler as Partner
https://www.optimumcomms.com/wp-content/uploads/2023/02/Pheon_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-10 08:34:532024-09-10 08:34:53Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki
https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-05 19:02:302024-09-05 19:02:30Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-05 17:00:052024-09-05 17:00:05Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-05 09:13:532024-09-05 09:13:53European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis (CTX)
https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-04 08:32:082024-09-04 08:32:08Vesper Bio announces successful Phase I study for potentially disease-modifying treatment for frontotemporal dementiaWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
